Please confirm topic selection

Are you sure you want to trigger topic in your Anconeus AI algorithm?

Updated: 2/28/2019

Fusion Inhibitors

0%
Topic
Review Topic
0
0
N/A
N/A
Questions
2
0
0
0%
0%
Evidence
2
0
0
Topic
  • Snapshot
    • A 55-year-old man presents to the HIV clinic for a follow-up visit. He was recently diagnosed with HIV and was started on first-line highly active antiretroviral therapy (HAART). However, his CD4 count at his last visit remained low. Drug resistance analysis of the HIV strain was sent at that time and revealed 3 major mutations causing the virus to be resistant to many first-line agents. The analysis also revealed that the HIV strain was CCR5-tropic. The patient was started on maraviroc.
  • Introduction
    • Drugs
      • enfuvirtide
        • prevents penetration of HIV into CD4+ T-cells
      • maraviroc
        • prevents attachment of HIV into CD4+ T-cells
    • Clinical use
      • a class of highly active antiretroviral therapy (HAART)
      • often used as second-line in patients with drug resistance to first-line agents
  • Enfuvirtide
    • Mechanism of action
      • binds to gp41, which inhibits HIV entry into the cell
    • Adverse effects
      • injection site skin reaction
      • gastrointestinal upset
      • fatigue
  • Maraviroc
    • Mechanism of action
      • binds to CCR5, which is a protein on the surface of T-cells and monocytes
      • inhibits the interaction of CCR5 with gp120 on HIV, thus inhibiting docking
    • Clinical use
      • requires assay showing that the virus is CCR5-tropic, which indicates that the virus is infecting cells with CCR5 expression (vs CXCR4), making it susceptible to the drug
    • Adverse effects
      • rash
      • gastrointestinal upset
      • immunosuppression

Please rate this review topic.

You have never rated this topic.

Thank you. You can rate this topic again in 12 months.

Flashcards (0)
Cards
1 of 0
Questions (2)
Question locked
Sorry, this question is for
PEAK Premium Subscribers only
Upgrade to PEAK

(M1.MC.15.75) A 25-year-old sexually active male presents to an internal medicine physician for a routine health check up after having several unprotected sexual encounters. After appropriate testing the physician discusses with the patient that he is HIV+ and must be started on anti-retroviral treatment. Which of the following medications prescribed acts on the gp41 subunit of the HIV envelope glycoprotein?

QID: 106845

Amantadine

3%

(9/329)

Rimantadine

2%

(5/329)

Zidovudine

17%

(56/329)

Saquinavir

6%

(21/329)

Enfuvirtide

71%

(235/329)

M 1 E

Select Answer to see Preferred Response

Evidence (2)
EXPERT COMMENTS (2)
Private Note